Unlock genomic data while preserving privacy.
A catalyst for discovery
As the global volume of genomic data grows, healthcare stakeholders – from drug manufacturers to policymakers – are realizing the disruptive potential of this new data source. From a better understanding of disease biology, to how treatments work in sub-populations, to evidence for alternative reimbursement models.
But finding efficient, scalable ways to conduct genomic research is essential. And reducing the fear around privacy concerns is paramount.
IQVIA's collaboration with Genomics England
The goal: to develop a best-in-class platform that connects clinical and non-identified genomic data to accelerate treatment advancements for patients. This alliance will enable faster and more efficient drug research, more robust evidence to support treatment value, and greater access to personalized medicines.
Advancing genomic research will accelerate the discovery of precision therapies, improve access and health outcomes, and deliver on the potential of Human Data Science.Rob Kotchie, president, Real World Solutions at IQVIA
Human Data Science advances genomic research
IQVIA is leading the charge in using Human Data Science – the necessary integration of data science and technology with human science expertise – to drive new discoveries and insights from increasingly complex datasets in healthcare.
Our unparalleled data assets, combined with advanced analytics and transformative technologies uniquely positions our teams to collect and protect the data that helps us answers questions about human health.
Our work in Human Data Science has been at the heart of how we are helping enable genomic research through partnerships, advanced analytics, and perhaps most importantly technology that supports patient privacy.
Expanding the queries
IQVIA is providing life science customers immediate access to aggregated data at scale to conduct a wide range of research. This research can help them identify new molecular targets for their pipeline and new indications for products by accessing non-identified data in a secure environment.
E360 Genomics
E360™ Genomics can manage the size and complexity of genomic datasets and draw insights from a myriad of covariates preserving privacy.
- Link comprehensive clinical data: Non-identified genomic data enables the critical linkage with a multitude of relevant data sources to create a holistic picture
- Balance patient privacy: Genomic data is non-identified at the patient level throughout the research process
- Aggregate data at scale: Non-identified genomic data encourages sharing between institutions by addressing privacy and competitive concerns
Researchers can now benefit from immediate access to data, data science and analytics at scale to complete research in a manner that allows for reuse, lower costs, faster results.
The result is accelerated genomic research, and a faster, more flexible, and less expensive approach for scientific enquiry into human biology, drug discovery and drug development.
Explore our end-to-end, full service clinical development capabilities including Therapeutics expertise, Development Planning, Phase I early clinical development, Phase IIb/III and Phase IV Trials, Regulatory Submission and Post-Launch Studies.
Access central labs around the globe through Q² Solutions, a joint venture between IQVIA and Quest Diagnostics.
Tap into evidence networks in oncology, neurology, immunology, and other therapy areas to enrich your studies.